Kim Schroer

Managing Associate

シカゴ +1 312 853 7033

ヘルスケア

- PDF letter
- PDF A4

Jump To

Biography

KIM SCHROER focuses her practice on healthcare regulatory and compliance matters. This includes advising clients on fraud and abuse issues involving the federal Anti-Kickback Statute and Stark Law, Medicare and Medicaid coverage and reimbursement, government price reporting laws, and the development of healthcare compliance programs. Kim advises a wide range of clients on these matters, including pharmaceutical manufacturers, medical device manufacturers, healthcare providers, and clinical laboratories.

Kim regularly counsels pharmaceutical manufacturers on state drug price transparency matters. In addition, she advises private equity firms and corporate clients on the wide variety of complex issues that arise in the context of mergers and acquisitions involving life sciences companies.

Kim received her J.D., cum laude, from Harvard Law School, where she was a legal intern at the U.S. Attorney’s Office for the District of Massachusetts. Kim graduated summa cum laude from Boston College with a degree in history and political science.

Credentials

Admissions & Certifications

Illinois

Education

ハーバード大学ロースクール, 法務博士, 2019, cum laude
Boston College, B.A., 2014, summa cum laude

Capabilities

News & Insights

Co-author, “CMS Announces Voluntary Most-Favored-Nation Pricing in Medicaid Through the GENEROUS Model,” Sidley Update, November 11, 2025.
Co-author, “CMS Finalizes Key Medicare Reimbursement Policies for Telehealth, Chronic Disease, and Digital Health,” Sidley Update, November 4, 2025.
Co-author, “Major Changes to U.S. Government Pricing Requirements Finalized, With Some Wins for Pharma and Biotech,” Sidley Update, November 3, 2025.
Co-author, “Key Medicare Reimbursement Policies Under the Microscope in Proposed Rule,” Sidley Update, July 24, 2025.
Co-author, “Major U.S. Government Price Reporting Proposals Warrant Industry Comment,” Sidley Update, July 18, 2025.
Co-author, “CMS Reverses Course on Certain Medicare Advantage and Part D Proposals and Further Implements Inflation Reduction Act,” Sidley Update, April 10, 2025.
Co-author, “Oregon’s Drug Price Transparency Law Deemed Unconstitutional by District Court,” Sidley Update, February 28, 2024.
Co-author, “Illinois Generic Drug Price Gouging Law Challenged; State Affordability Boards May Draw Similar Fire,” Sidley Update, February 9, 2024.
Co-author, Cell and Gene Therapies Access Model on Sickle Cell Disease Announced by U.S. CMS Innovation Center,” Sidley Update, February 6, 2024.
Co-author, “State Scrutiny Of Drug Pricing Intensifies With Rise Of PDABs,” Life Science Leader, August 1, 2023.
Co-author, “The Business Case for Healthcare Compliance Programs for Emerging Companies,” Outscored Pharma, June 9, 2023.
Co-author, “CMS Seeks to Reverse Prior Stacking Guidance and Proposes Novel Transparency Requirements for “High-Cost Drugs”,” Sidley Update, May 31, 2023.
Co-author, “U.S. Territories Now Permitted to Participate in the Medicaid Drug Rebate Program: What Does This Mean for Manufacturers?” Sidley Update, February 8, 2023.
Co-author, “This Is Your Wake-Up Call – Sunshine Act Enforcement Is Here,” Pharmaceutical Executive, March 21, 2021.